Analysts Have Made A Financial Statement On Travere Therapeutics, Inc.'s (NASDAQ:TVTX) First-Quarter Report
A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $22 to $30
Express News | Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $30 Price Target
Travere Therapeutics Is Maintained at Hold by Stifel
Travere Therapeutics Analyst Ratings
Express News | Travere Therapeutics Inc : Stifel Raises Target Price to $23 From $22
TD Cowen Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $30
Earnings Call Summary | Travere Therapeutic(TVTX.US) Q1 2025 Earnings Conference
Travere Therapeutics Anticipates FILSPARI Approval for FSGS by September 2025
Travere Therapeutic | 8-K/A: Travere Therapeutics Reports First Quarter 2025 Financial Results
Travere Therapeutic | 10-Q: Q1 2025 Earnings Report
$TVTX Earnings Results: $TVTX Reports Quarterly Earnings
Travere Therapeutics 1Q Loss/Shr 47c >TVTX
Earnings Flash (TVTX) Travere Therapeutics Reports Q1 Revenue $81.7M, Vs. FactSet Est of $77.3M
Travere Therapeutic | 8-K: Travere Therapeutics Reports First Quarter 2025 Financial Results
Express News | Travere Therapeutics Q1 Operating Income USD -42.674 Million Vs. IBES Estimate USD -47.2 Million
Express News | Travere Therapeutics Q1 EPS USD -0.47 Vs. IBES Estimate USD -0.54
Press Release: Travere Therapeutics Reports First Quarter 2025 Financial Results
Earnings Scheduled For May 1, 2025
Travere, CSL Gets Standard EU Approval for Kidney Disorder Treatment